Piper Sandler analyst Yasmeen Rahimi upgraded Aligos Therapeutics to Overweight from Neutral with a price target of $3, up from $2.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALGS:
- Jefferies upgrades Aligos to Buy on derisking of NASH pill
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial